Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Satisfies DoJ ‘Need To Know’ About Probiotic Claim Studies

This article was originally published in The Tan Sheet

Executive Summary

A judge also grants Bayer’s request to depose an FTC attorney about the agency’s investigation that led to a contempt charge linked to allegedly violating a 2007 consent decree by making a drug claim for the Phillips’ Colon Health three-bacteria-strain formula.

You may also be interested in...

Bayer Probiotic Claim Defense Argues FTC Wants Substantiation Standard That ‘Did Not Exist’

DoJ says Bayer is avoiding answering requests for details on research that substantiates claims for Philip’s Colon Health and asks a judge to “resolve this matter.” Bayer says it has answered DoJ’s interrogatories, stating it could not comply with FTC’s alleged “standard because it did not exist until” the complaint was filed.

Pataday Switch Appoval Dilates Eye Drop Category As Alcon's OTC Sales Driver

With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts